Immunotherapy News and Research

Latest Immunotherapy News and Research

Einstein researchers awarded $2.6 million NIH grant to develop effective cancer immunotherapies

Einstein researchers awarded $2.6 million NIH grant to develop effective cancer immunotherapies

CHLA receives grant to study effects of chemoimmunotherapy in childhood neuroblastoma

CHLA receives grant to study effects of chemoimmunotherapy in childhood neuroblastoma

Chemotherapy leads to drug-resistance in bladder cancer patients

Chemotherapy leads to drug-resistance in bladder cancer patients

NAC improves effectiveness of adoptive cell therapy for treating melanoma

NAC improves effectiveness of adoptive cell therapy for treating melanoma

Long-term clinical data, experience supports effectiveness of PRRT for treating neuroendocrine tumors

Long-term clinical data, experience supports effectiveness of PRRT for treating neuroendocrine tumors

FAAM 2016: Experts discuss advancements in diagnosis, management of food allergies and anaphylaxis

FAAM 2016: Experts discuss advancements in diagnosis, management of food allergies and anaphylaxis

Mount Sinai awarded $10 million grant to explore cellular, molecular mechanisms of GVHD

Mount Sinai awarded $10 million grant to explore cellular, molecular mechanisms of GVHD

Houston Methodist researcher receives $4 million to create triple negative breast cancer immunotherapy

Houston Methodist researcher receives $4 million to create triple negative breast cancer immunotherapy

Study suggests possibility for small molecule drug/antibody combinatorial therapy to treat neuroblastoma

Study suggests possibility for small molecule drug/antibody combinatorial therapy to treat neuroblastoma

Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Researchers explain why explain why some tumors recur after immunotherapy

Researchers explain why explain why some tumors recur after immunotherapy

Survey reveals inequalities in access to new, life saving drugs for melanoma in Europe

Survey reveals inequalities in access to new, life saving drugs for melanoma in Europe

Study finds neoadjuvant immunotherapy safe, viable for early lung cancer patients before surgery

Study finds neoadjuvant immunotherapy safe, viable for early lung cancer patients before surgery

Women may have better verbal memory skills than men during early stages of Alzheimer's disease

Women may have better verbal memory skills than men during early stages of Alzheimer's disease

New study reveals CAR T cells can function as micro-pharmacies for precise therapeutic delivery

New study reveals CAR T cells can function as micro-pharmacies for precise therapeutic delivery

Immunotherapy already in clinical trials for cancer could slow progression of Parkinson's disease

Immunotherapy already in clinical trials for cancer could slow progression of Parkinson's disease

Recycling existing drugs may help fight several types of cancer

Recycling existing drugs may help fight several types of cancer

T-Bear brings hope to kids diagnosed with cancer at Seattle Children's Hospital

T-Bear brings hope to kids diagnosed with cancer at Seattle Children's Hospital

Single high-intensity SBRT dose can be effective in treating early stage NSCLC patients

Single high-intensity SBRT dose can be effective in treating early stage NSCLC patients

Combination of different drugs could improve effect of immunotherapy on skin cancer

Combination of different drugs could improve effect of immunotherapy on skin cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.